NCT07319169Not yet recruiting
The Value of Spleen Stiffness Measurement in Patients With PBC
Source: ClinicalTrials.gov · Last updated 1 May 2026
Brief summary (registry, in English)
Recent evidence suggests that combining liver stiffness measurement (LSM) with spleen stiffness measurement (SSM) significantly improves risk stratification in patients with PBC. In a study the addition of spleen stiffness to liver stiffness enhanced the prediction of liver decompensation, providing a more precise evaluation of portal hypertension. Furthermore, when combined with platelet count, this approach effectively identified patients with a low probability of harboring HRVs. This could allow clinicians to safely avoid unnecessary endoscopic procedures in selected patients, improving patient comfort and reducing healthcare costs. Therefore, our patients participating in this trial will undergo follow up (every 6 months) as per Standard of care. This includes a blood draw, FibroScan and Ultrasound. Together with this, 2 questionnaires will be completed (not as per SOC) and during the FibroScan, a spleen stiffness measurement will be performed.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 125 (estimated)
- First submitted
- 5 Dec 2025
- Start date
- 1 Jul 2026
- Primary completion date
- 31 Jan 2028
- Lead sponsor
- Universitair Ziekenhuis Brussel
- Diseases
- Primary biliary cholangitis
- NCT number
- NCT07319169
What you commit to
- Study type: Interventional
- Planned participants: 125
- From 1 Jul 2026 to the primary completion date, 31 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Contra-indication for transient elastography (Fibroscan®) such as ascites or overt heart failure.
Other
- \<18y
Who the study is looking for
- ≥18y
- Out-patient, followed at the UZ Brussels
- Diagnosis of PBC based on cholestasis, AMA positivity and/or biopsy.
- Under treatment with ursodeoxycholic acid and/or bezafibrate
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UZ Brussel Coordinator of this site? Confirm its status | Brussels | Belgium | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.